Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
11
04
2021
accepted:
19
07
2021
entrez:
7
10
2021
pubmed:
8
10
2021
medline:
8
10
2021
Statut:
epublish
Résumé
Breath analysis is a burgeoning field, with interest in volatile organic compounds (VOCs) as a noninvasive diagnostic tool or an outcome measure, but no randomised controlled trials (RCTs) have yet evaluated this technology in a clinical trial longitudinally. In a pilot RCT, our exploratory objectives were feasibility of measuring VOCs 43 participants had VOCs and sputum biomarkers evaluated. VOCs and induced sputum were collected after 6 h of fasting at screening and at days 1, 7 and 14. VOCs were analysed A joint-effects model demonstrated a modest relationship between four exhaled VOCs and VOC measurement in clinical trials to identify subsets of COPD is feasible, but assessment of new VOC technologies must include concurrent GC-MS validation. Further work to standardise collection of VOCs and measuring a background or "housekeeper" VOC is required to understand and normalise individual VOC quantities.
Sections du résumé
BACKGROUND
BACKGROUND
Breath analysis is a burgeoning field, with interest in volatile organic compounds (VOCs) as a noninvasive diagnostic tool or an outcome measure, but no randomised controlled trials (RCTs) have yet evaluated this technology in a clinical trial longitudinally. In a pilot RCT, our exploratory objectives were feasibility of measuring VOCs
METHOD
METHODS
43 participants had VOCs and sputum biomarkers evaluated. VOCs and induced sputum were collected after 6 h of fasting at screening and at days 1, 7 and 14. VOCs were analysed
RESULTS
RESULTS
A joint-effects model demonstrated a modest relationship between four exhaled VOCs and
CONCLUSIONS
CONCLUSIONS
VOC measurement in clinical trials to identify subsets of COPD is feasible, but assessment of new VOC technologies must include concurrent GC-MS validation. Further work to standardise collection of VOCs and measuring a background or "housekeeper" VOC is required to understand and normalise individual VOC quantities.
Identifiants
pubmed: 34616836
doi: 10.1183/23120541.00253-2021
pii: 00253-2021
pmc: PMC8488227
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: D. Mohan is a current employee and shareholder of Genentech/Roche. Conflict of interest: H.R. Keir has nothing to disclose. Conflict of interest: H. Richardson has nothing to disclose. Conflict of interest: D. Mayhew is a former employee of and shareholder in GSK. Conflict of interest: J. Boyer is a former employee of and shareholder in GSK. Conflict of interest: M.P. van der Schee is an employee of Owlstone Medical Ltd and holds options in the company. Conflict of interest: M.D. Allsworth is an employee of Owlstone Medical Ltd and holds options in the company. Conflict of interest: B.E. Miller is a former employee of and shareholder in GSK. Conflict of interest: R. Tal-Singer is a former employee of and shareholder in GSK, and has received personal fees from Immunomet, Vocalis Health and Ena Respiratory. Conflict of interest: J.D. Chalmers reports grants and personal fees from GSK during the conduct of the study; and research grants from Boehringer Ingelheim (BI), AstraZeneca (AZ), Gilead Sciences, Grifols and Insmed, and has received personal fees from BI, AZ, Chiesi, Grifols, Napp, Novartis, Insmed and Zambon.
Références
PLoS One. 2017 Dec 18;12(12):e0188879
pubmed: 29252995
J Allergy Clin Immunol. 2018 Jan;141(1):117-127
pubmed: 28506850
J Breath Res. 2016 Apr 15;10(2):026006
pubmed: 27082437
Chest. 2019 Aug;156(2):269-276
pubmed: 30685334
Eur Respir J. 2016 Apr;47(4):1082-92
pubmed: 26917613
Genetics. 1994 Nov;138(3):963-71
pubmed: 7851788
J Breath Res. 2016 Jun 16;10(3):036001
pubmed: 27310311
Int J Chron Obstruct Pulmon Dis. 2018 May 01;13:1441-1448
pubmed: 29750030
J Breath Res. 2018 Mar 06;12(3):036002
pubmed: 29295966
J Breath Res. 2016 Aug 31;10(3):034002
pubmed: 27578038
Am J Respir Crit Care Med. 2019 Aug 15;200(4):444-453
pubmed: 30973757
J Breath Res. 2013 Mar;7(1):016002
pubmed: 23257711
Am J Pathol. 2011 Jul;179(1):199-210
pubmed: 21703402
ERJ Open Res. 2020 Nov 10;6(4):
pubmed: 33263062
J Breath Res. 2012 Sep;6(3):036003
pubmed: 22759349
Eur Respir J. 2021 May 20;57(5):
pubmed: 33542054
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
PLoS One. 2015 Sep 09;10(9):e0135199
pubmed: 26353114
Eur Respir J. 2018 Oct 4;52(4):
pubmed: 30139779
Eur Respir J. 2018 Apr 12;51(4):
pubmed: 29449427
Eur Respir J. 2020 Mar 26;55(3):
pubmed: 31949116
Thorax. 2018 May;73(5):422-430
pubmed: 29386298
J Thromb Haemost. 2016 Jan;14(1):191-204
pubmed: 26484898
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Microbiology (Reading). 2012 Dec;158(Pt 12):3044-3053
pubmed: 23059976